Astellas OSI Bid, PTV News: Mar 02, 2010




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Astellas OSI Bid, PTV News: Mar 02, 2010
Released on: March 02, 2010. © PharmaVentures Ltd
Visitors: You are watching a 1 minute preview.
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
Japanese drugmaker to take US$ 3.5B offer to shareholders
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Jansen Jacob
Analyst
PharmaVentures

Jansen’s expertise lies in transactions, business strategy & planning as well as market and competitor analysis. His skills include product and technology valuations, benchmarking, deal structuring and litigation support in the pharmaceutical sector. With over 15 years in the life science sector Jansen’s experience covers DNA therapeutics, immunotherapy, animal health and plant science research. Jansen holds a chemistry degree from Gandhiji University, a DPhil in Biochemistry from the University of Sussex and an MBA from Oxford Brookes University.
Astellas Pharma
Astellas Pharma Inc., to fulfill its business philosophy to "Contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products," is actively engaged in business as an R&D-driven global pharmaceutical company.
OSI Pharmaceuticals
OSI Pharmaceuticals is committed to “shaping medicine and changing lives” by discovering, developing and commercializing high-quality, novel and differentiated targeted medicines designed to extend life and improve the quality of life for patients with cancer and diabetes/obesity.